Trial · NCT06967857
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
NCT06967857, Phase 2, Recruiting, Prof. Dr. Frank Behrens
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression. Trials, record NCT06967857. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06967857
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
- NCT number
- NCT06967857
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 105 participants, estimated
- Lead sponsor
- Prof. Dr. Frank Behrens
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder
- Interventions
- DEX IR tablets, DEX XL, Placebo
- First posted
- 2025-05-13
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes62
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse events (AE) in the active treatment groups compared to the placebo until V6 | from enrollment to the end of study at week 17 | Incidence of adverse events (AE) in the active treatment groups (DEX XL and DEX IR) compared to the placebo until V6 |
| Secondary | Incidence of adverse events (AE) until V5 | Start with enrollment until end of treatment at Week 16 | Dokumentation of AE |
| Secondary | Proportion of patients with at least one AE until V5 | through study treatment (up to 16 weeks) | Proportion of patients with at least one AE until V5 |
| Secondary | Proportion of patients with at least one AE until end of study | from baseline until end of study at week 17 | Proportion of patients with at least one AE until end of study |
| Secondary | Number of AE until V5 | through study treatment (up to 16 weeks) | Number of AE |
| Secondary | Number of AE until V5 and until end of study | from baseline until end of study at week 17 | Number of AE |
| Secondary | Number of AE/SAE during the study period | through study treatment (up to 16 weeks) | Number of AE/SAE |
| Secondary | number of patients with AE/SAE by type during study period | through study treatment (up to 16 weeks) | Number and type of AE/SAE |
| Secondary | proportion of patients with AE/SAE by type during study period | through study treatment (up to 16 weeks) | Proportion of patient with AE/SAE by type |
| Secondary | number of patients with AE/SAE by severity (mild, moderate, severe) during study period | through study treatment (up to 16 weeks) | number of patients with AE/SAE by severity (mild, moderate, severe) |
1 to 10 of 62Source ClinicalTrials.gov
See all 62 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06967857
GET https://conductscience.org/api/trials/v1/NCT06967857/registered?page=2